Clinical Research

Getinge announces results from SEMPER FI pilot study of intra-aortic balloon pump showing numerical trend toward reduced mortality in patients with extensive myocardial infarction and persistent ischemia

WAYNE, N.J., May 25, 2018 — Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study.

May 30, 2018
Abbott's Tendyne TMVR device | Mitral valve replacement

TMVR device nearly wipes out mitral regurgitation

An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

May 24, 2018

Independent Stent Imaging Study Shows Excellent Healing Profile with Resolute Onyx DES in Complex Patients with Coronary Artery Disease

DUBLIN and PARIS — May 24, 2018 — Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that contained a high percentage of patients with complex coronary artery disease who were implanted with the Resolute Onyx(TM) DES at one-month follow-up.

May 24, 2018

New ORBITA data: Freedom from angina, stress echos improved with PCI

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

May 22, 2018
EuroPCR 2018 logo

FFR-guided PCI linked to better 5-year outcomes than medical therapy

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

May 22, 2018

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

May 3, 2018

Exercise interventions for PAD may require personal support

A randomized trial published April 24 in JAMA suggests patients with lower-extremity peripheral artery disease (PAD) can’t be expected to improve walking performance on their own, even with the aid of wearable activity trackers and telephone coaching sessions.

April 25, 2018
Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?

After ORBITA: Looking at Angina Through a New Lens

Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?

February 28, 2018

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup